EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study

Marlise R Luskin iD, Jun Yin, Gerard Lozanski, Emily Curran, Gregory Malnassy, Krzysztof Mrózek, Clara D Bloomfield, Spero R Cataland, Noreen Fulton, Jonathan Kolitz, Betsy Laplant, Oudom Kour und 8 weitere

Cancer · 2025

DOI: 10.1002/cncr.35750 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, 2025. Verfasst von Marlise R Luskin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Alemtuzumab, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Bayer, Sanofi Genzyme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long‐term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B‐ and T‐lineage ALL. Alemtuzumab, a humanized immunoglobulin G1 monoclonal antibody that targets CD52, was identified as a potential agent to improve treatment efficacy without increasing toxicity.

Methods

In this phase 1/2 study (Cancer and Leukemia Group B [CALGB] 10102, NCT00061945), a course of single‐agent alemtuzumab was intercalated into CALGB 19802 backbone chemotherapy after the third course of intensive chemotherapy in those who were CD52+ at diagnosis. Phase 1 tested three dose levels of subcutaneous alemtuzumab (10, 20, and 30 mg 3 times weekly for 4 weeks/12 doses) and demonstrated that 30 mg was tolerable. Phase 2 established feasibility.

Results

The study enrolled 295 evaluable patients (115 in phase 1, 180 in phase 2); 206 (69.8%) were CD52+. Among evaluable CD52+ patients, 43.7% (90/206) completed the first three treatment modules; 97.8% (88 of 90) were treated with alemtuzumab. Alemtuzumab was associated with cytomegalovirus viremia, which occurred in 23.3% (14 of 60) of patients during and 29.2% (19 of 65) after alemtuzumab treatment. With a median follow‐up of 101.2 months, median overall survival (OS) was 26.3 months (3‐year rate, 44%; 5‐year rate, 36%; 10‐year rate, 31%). Landmark analysis at the start of the fourth course of treatment demonstrated no difference in OS or disease‐free survival between patients who did and who did not receive alemtuzumab.

Conclusion

Alemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlemtuzumabPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansMiddle AgedFemaleAdultMaleAgedYoung AdultCD52 AntigenAdolescentAged, 80 and overTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

ALLalemtuzumabantibodychemotherapymonoclonalolder

Substanzen

AlemtuzumabCD52 AntigenCD52 protein, humanAntineoplastic Agents, ImmunologicalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida, USA.
  • Department of Pathology, The Ohio State University Medical Center, Columbus, Ohio, USA.
  • University of Cincinnati Cancer Center, Cincinnati, Ohio, USA.
  • Department of Pathology, University of Chicago, Chicago, Illinois, USA.
  • Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.

ORCID-Profile: Marlise R Luskin, Eunice S Wang, Richard A Larson

Förderung

  • NCI NIH HHS
  • Bayer
  • Sanofi Genzyme
  • National Cancer Institute

Zitieren

APA

Luskin, M. R., Yin, J., Lozanski, G., Curran, E., Malnassy, G., Mrózek, K., Bloomfield, C. D., Cataland, S. R., Fulton, N., Kolitz, J., Laplant, B., Kour, O., Powell, B. L., Vij, R., Wang, E. S., Grinblatt, D., Stone, R. M., Uy, G. L., Larson, R. A., & Stock, W. (2025). Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. Cancer. https://doi.org/10.1002/cncr.35750

Vancouver

Luskin MR, Yin J, Lozanski G, Curran E, Malnassy G, Mrózek K, et al. Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. Cancer. 2025. doi:10.1002/cncr.35750

BibTeX
@article{Luskin2025,
  author = {Luskin, Marlise R and Yin, Jun and Lozanski, Gerard and Curran, Emily and Malnassy, Gregory and Mrózek, Krzysztof and Bloomfield, Clara D and Cataland, Spero R and Fulton, Noreen and Kolitz, Jonathan and Laplant, Betsy and Kour, Oudom and Powell, Bayard L and Vij, Ravi and Wang, Eunice S and Grinblatt, David and Stone, Richard M and Uy, Geoffrey L and Larson, Richard A and Stock, Wendy},
  title = {Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35750}
}
Kostenlos starten →